| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/28/2001 | WO2001046475A1 Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046455A2 Survivin promotion of angiogenesis |
| 06/28/2001 | WO2001046450A1 Replication incompetent herpes virus vectors |
| 06/28/2001 | WO2001046449A1 Replication incompetent herpes viruses for use in gene therapy |
| 06/28/2001 | WO2001046408A2 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 06/28/2001 | WO2001046392A2 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | WO2001046386A1 Progressive elevated gene-3 (peg-3) induces aggressive cancer phenotype and regulates angiogenesis |
| 06/28/2001 | WO2001046384A2 A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| 06/28/2001 | WO2001046383A2 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 06/28/2001 | WO2001046255A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046254A1 Transferrin polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | WO2001046247A1 A new polypeptide-subtilopeptidase 9 and the polynucleotide encoding it |
| 06/28/2001 | WO2001046228A2 Nucleic acid vaccination |
| 06/28/2001 | WO2001046225A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 06/28/2001 | WO2001046224A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 06/28/2001 | WO2001046175A1 Diamidine compounds as dna minor groove binders |
| 06/28/2001 | WO2001045751A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | WO2001045749A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | WO2001045748A1 Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| 06/28/2001 | WO2001045747A1 Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
| 06/28/2001 | WO2001045735A2 Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen |
| 06/28/2001 | WO2001045731A1 Particulate drug-containing products and method of manufacture |
| 06/28/2001 | WO2001045730A2 Tweak receptor |
| 06/28/2001 | WO2001045672A2 Mixed structures resulting from the incorporation of a biological macromolecule in a liquid crystal phase of amphiphiles |
| 06/28/2001 | WO2001045548A2 Surgical needle with weeping tip and method of use |
| 06/28/2001 | WO2001045510A1 Adeno-associated vectors for expression of factor viii by target cells |
| 06/28/2001 | WO2001021766A3 Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells |
| 06/28/2001 | WO2001014402A8 Antisense modulation of focal adhesion kinase expression |
| 06/28/2001 | WO2001002561A3 Mammalian calcium channels and related probes, cell lines and methods |
| 06/28/2001 | WO2000078357A3 Hyaluronic acid film and matrix for sustained gene transfer |
| 06/28/2001 | WO2000077038A3 P202 is a tumor suppressor |
| 06/28/2001 | WO2000076450A3 Recombinant adenoviruses for the sodium/iodide symporter (nis) |
| 06/28/2001 | WO2000075291A3 Cells with enforced expression of bcl-xl |
| 06/28/2001 | WO2000073452A3 Compositions and methods for the treatment of immune related diseases |
| 06/28/2001 | WO2000073344A3 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 06/28/2001 | WO2000070047A3 Full-length molecules expressed in human tissues |
| 06/28/2001 | WO2000068247A3 Serine proteases |
| 06/28/2001 | WO2000067697A3 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 06/28/2001 | WO2000066708A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/28/2001 | WO2000061753A3 Compositions and methods for the treatment and diagnosis of breast cancer |
| 06/28/2001 | WO2000061180A3 Products and methods for treating ptp lar related diseases |
| 06/28/2001 | WO2000055194A3 Tuberculosis antigens and methods of use therefor |
| 06/28/2001 | WO2000044774A3 Inhibition of stat3 signal transduction for human cancer therapy |
| 06/28/2001 | WO1997046686A3 Tumor necrosis factor-related polypeptide |
| 06/28/2001 | US20010005717 Gene transfer complexes of a polyethyleneimine having a hydrophilic polymer such as polyoxyethylene glycol coupled thereto, and a nucleic acid; use in gene therapy |
| 06/28/2001 | US20010005505 Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
| 06/28/2001 | DE19962583A1 New antibodies specific for plasma cells, useful for treatment and diagnosis of autoimmune diseases and plasma cell tumors |
| 06/28/2001 | DE19959045A1 Adeno-associated virus vectors that express monocyte chemotactic protein-1, useful for gene therapy of cancers, promotion of angiogenesis and treatment of inflammation |
| 06/28/2001 | DE19957065A1 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 06/28/2001 | CA2395578A1 Replication incompetent herpes virus vectors |
| 06/28/2001 | CA2395576A1 Replication incompetent herpes viruses for use in gene therapy |
| 06/28/2001 | CA2395525A1 Transferrin polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2395435A1 Cosmid dna constructs and methods of making and using the same |
| 06/28/2001 | CA2395429A1 Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
| 06/28/2001 | CA2395269A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 06/28/2001 | CA2395208A1 Nucleic acid vaccination |
| 06/28/2001 | CA2395136A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | CA2394860A1 Hypodermic needle with weeping tip and method of use |
| 06/28/2001 | CA2394822A1 Mixed structures resulting from the incorporation of a biological macromolecule, particularly dna, into a liquid-crystal phase of amphiphiles, and vesicles obtained from these structures |
| 06/28/2001 | CA2394015A1 Tweak receptor |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393646A1 Survivin promotion of angiogenesis |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392150A1 Diamidine compounds as dna minor groove binders |
| 06/28/2001 | CA2391594A1 Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2355345A1 Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
| 06/27/2001 | EP1111048A2 Neutral amino acid transporter and gene thereof |
| 06/27/2001 | EP1111041A1 Systemic carnitine deficiency gene and utilization thereof |
| 06/27/2001 | EP1109926A1 Condensed plasmid-liposome complex for transfection |
| 06/27/2001 | EP1109925A1 Recombinant adenovirus for tissue specific expression in heart |
| 06/27/2001 | EP1109924A2 Methylation of plasmid vectors |
| 06/27/2001 | EP1109921A1 Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| 06/27/2001 | EP1109914A2 Inhibition of smooth muscle cell migration by heme oxygenase 1 |
| 06/27/2001 | EP1109908A2 Leptin induced genes |
| 06/27/2001 | EP1109907A1 Human cell junction pdz protein |
| 06/27/2001 | EP1109906A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus |
| 06/27/2001 | EP1109905A1 Genes encoding for the human and murine death inducer-obliterator-1 |
| 06/27/2001 | EP1109904A1 Novel molecules of the herpes virus-entry-mediator-related protein family and uses thereof |
| 06/27/2001 | EP1109896A1 Adenovirus formulations for gene therapy |
| 06/27/2001 | EP1109833A2 Compositions and methods for the treatment of tumors |
| 06/27/2001 | EP1109829A1 Human latent transforming growth factor beta binding protein 3 |
| 06/27/2001 | EP1109824A1 Novel bag proteins and nucleic acid molecules encoding them |
| 06/27/2001 | EP1109821A1 49 human secreted proteins |
| 06/27/2001 | EP1109582A1 Methods to enhance and confine expression of genes |
| 06/27/2001 | EP1109577A1 Multicomponent vaccines |
| 06/27/2001 | EP1109571A2 Methods of treating hypertension and compositions for use therein |
| 06/27/2001 | EP1109570A2 Method of modulating memory effector t-cells and compositions |
| 06/27/2001 | EP1109569A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 06/27/2001 | EP1109566A1 Gcp |
| 06/27/2001 | EP1109565A1 Gabab1aa receptor |
| 06/27/2001 | EP1109559A2 Inhibition of pathogenic processes related to tissue trauma |
| 06/27/2001 | EP1109539A1 Nanogel networks and biological agent composition thereof |
| 06/27/2001 | EP1109454A2 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| 06/27/2001 | EP0577648B1 Novel protein polycation conjugates |
| 06/27/2001 | CN1301311A Detection of DNA, RNA and proteins |
| 06/27/2001 | CN1301298A Methods for prevention and treatment of cancer |
| 06/27/2001 | CN1301182A Solid preparations for oral administration of drugs relating to genes |
| 06/27/2001 | CN1301181A Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 06/27/2001 | CN1301180A Recombinant i(mycoplasma hyopneumoniae) vaccine |
| 06/27/2001 | CN1300848A Polypeptide-nagarase 9 and polynucleotide for coding this polypeptide |